A Look At BridgeBio Pharma (BBIO) Valuation After Recent Share Price Volatility

Simply Wall St.03-12

AdvertisementWhat BridgeBio Pharma’s recent performance tells you right now BridgeBio Pharma (BBIO) has drawn fresh attention after recent share price moves, including a 3.9% decline over the past day...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2618130908?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-03-12 22:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618130908","market":"hk","top_or_hot":-1,"title":"A Look At BridgeBio Pharma (BBIO) Valuation After Recent Share Price Volatility","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementWhat BridgeBio Pharma’s recent performance tells you right now BridgeBio Pharma (BBIO) has drawn fresh attention after recent share price moves, including a 3.9% decline over the past day...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bbio/bridgebio-pharma/news/a-look-at-bridgebio-pharma-bbio-valuation-after-recent-share\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At BridgeBio Pharma (BBIO) Valuation After Recent Share Price Volatility</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At BridgeBio Pharma (BBIO) Valuation After Recent Share Price Volatility\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-12 22:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bbio/bridgebio-pharma/news/a-look-at-bridgebio-pharma-bbio-valuation-after-recent-share><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementWhat BridgeBio Pharma’s recent performance tells you right now BridgeBio Pharma (BBIO) has drawn fresh attention after recent share price moves, including a 3.9% decline over the past day...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bbio/bridgebio-pharma/news/a-look-at-bridgebio-pharma-bbio-valuation-after-recent-share\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bbio/bridgebio-pharma/news/a-look-at-bridgebio-pharma-bbio-valuation-after-recent-share","article_id":"2618130908","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bbio/bridgebio-pharma/news/a-look-at-bridgebio-pharma-bbio-valuation-after-recent-share","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2618130908","pubTimestamp":1773325644,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"What BridgeBio Pharma’s recent performance tells you right now\nBridgeBio Pharma (BBIO) has drawn fresh attention after recent share price moves, including a 3.9% decline over the past day and mixed returns over the past week, month, and past 3 months. This has prompted investors to reassess the story.\nSee our latest analysis for BridgeBio Pharma.\nZooming out, BridgeBio Pharma’s recent pullback sits alongside a mixed stretch of share price returns over the past quarter and year to date, while...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","BBIO":"BridgeBio Pharma, Inc.","BK4505":"高瓴资本持仓","BK4139":"生物科技"},"translate_title":"近期股价波动后BridgeBio Pharma(BBIO)估值一览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BBIO":1.5},"content_text":"AdvertisementWhat BridgeBio Pharma’s recent performance tells you right now BridgeBio Pharma (BBIO) has drawn fresh attention after recent share price moves, including a 3.9% decline over the past day and mixed returns over the past week, month, and past 3 months. This has prompted investors to reassess the story. See our latest analysis for BridgeBio Pharma. Zooming out, BridgeBio Pharma’s recent pullback sits alongside a mixed stretch of share price returns over the past quarter and year to date, while its 1 year total shareholder return above 100% reflects a strong longer term payoff for investors who stayed the course. If this kind of volatility has you looking beyond a single biotech name, it could be a good moment to explore other healthcare names using our 34 healthcare AI stocks as a starting list of ideas. So, with a 1-year return above 100%, recent quarterly softness, and a current price of $71.39 against a published target of about $99.96, is BridgeBio still offering upside, or is the market already pricing in future growth? Most Popular Narrative: 28.6% Undervalued With BridgeBio Pharma last closing at $71.39 against a fair value of $100.05 from the most followed narrative, the gap between story and price is clear and invites a closer look at what is driving that view.  Following the commercial success of its flagship stabilizer, Attruby (acoramidis), which generated a record $146 million in Q4 2025 net product revenue, BridgeBio is preparing to triple its commercial portfolio. In a historic \"three-for-three\" run, the company delivered positive Phase 3 readouts for encaleret (ADH1), BBP-418, and infigratinib (achondroplasia) in just over 90 days.  Read the complete narrative. What kind of revenue ramp, profit potential, and valuation multiple gets you from today’s price to that fair value? The narrative leans heavily on rare disease pricing power, accelerating revenue from the existing product, and a future profit profile more often associated with mature large caps. Curious which assumptions matter most and how they fit together over the next few years? According to Vestra, the fair value of $100.05 rests on a view that BridgeBio Pharma is evolving from an R&D heavy loss maker into a multi product commercial player, supported by forecast revenue growth, improving margins and a future earnings multiple applied to those projected profits. The current share price of $71.39 sits below that narrative fair value, highlighting a clear difference between this valuation framework and where the market is pricing the stock today. Result: Fair Value of $100.05 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this story can still be knocked off course by clinical or regulatory setbacks on key programs, or slower than expected uptake for Attruby. Find out about the key risks to this BridgeBio Pharma narrative. Another angle on valuation: rich on sales, cheap on cash flows? The $100.05 fair value from the narrative points to upside, but the picture gets trickier when you look at sales. BBIO trades on a P/S of 27.6x, well above the US biotechs average of 12.4x and also above its own fair ratio of 22.8x, which points to a full price on current revenues. This raises the question of whether investors are paying a premium today in the expectation that the growth story fully materializes. See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:BBIO P/S Ratio as at Mar 2026Next Steps If this mix of optimism and caution around BridgeBio resonates with you, do not wait; weigh the evidence yourself and see both sides of the story. Then take a moment to review the full balance of 2 key rewards and 1 important warning sign before you decide how it fits in your portfolio. Ready to look beyond one stock? If BridgeBio has sharpened your thinking, do not stop here. Broaden your watchlist now so you are not looking back wishing you had checked other ideas.  Spot potential mispricings early by reviewing our 50 high quality undervalued stocks that pair solid fundamentals with price tags that may not fully reflect their qualities. Strengthen your income stream by scanning 14 dividend fortresses built around higher yielding payers with an emphasis on durability. Protect your downside by hunting through the 67 resilient stocks with low risk scores focused on companies with more resilient risk profiles.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if BridgeBio Pharma might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618130908","isCrawlerRequest":true}